Cipla and Dr Reddys Lab receives FDA nod for marketing of generic version of REVLIMID (lenalidomide) Capsules. Both companies have received final approval of its Abbreviated New Drug Application (ANDA) for Lenalidomide Capsules.
With this volume-limited launch, Dr. Reddy’s Lab is eligible for first-to- market, 180 days of generic drug exclusivity for Lenalidomide Capsules in 2.5 mg and 20 mg strengths.
- Read more about Cipla and Dr Reddys Lab receives FDA nod for Cancer medicine
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/cipla-and-dr-reddys-lab-receives-fda-nod-for-cancer-medicine
No comments:
Post a Comment